22 February 2021
Visiongain has published a new report on Traveller’s Diarrhoea Treatment Market Report 2021-2031: Forecasts By Drug Class (Oral Rehydration Therapy (ORS), Antidiarrheal Agents, Vaccines/prophylactics, and Others), By Pathogen (Bacteria, Viruses, Protozoa, and Giardiasis), By Route of Administration (Oral, and Parenteral), By Patient Demographics (Adults, and Pediatric), By End User (Hospital, Homecare, Specialty Clinics, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Traveler’s Diarrhea Treatment was valued at US$ xx Million in 2020 and is projected to reach a market value of US$ xx Million by 2031. North America dominated the global Traveler’s Diarrhea Treatment and is projected to witness a CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Traveler’s Diarrhea Treatment
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Traveler’s Diarrhea Treatment. Different recovery scenarios are also included in the report for all the segments and regions/nations. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Traveler's diarrhea
The burden of traveler's diarrhea is increasing and it is expected that traveler's diarrhea prevalence will increase during the forecast period. The prevalence of traveler's diarrhea is increasingly caused by eating contaminated food or drinking contaminated water. Increasing traveler's diarrhea cases creates a huge demand for the traveler's diarrhea treatment. Due to which the increasing prevalence of traveler's diarrhea is working as a driver for the traveler’s diarrhea treatment market.
Government initiative and awareness program
Governments around the world are launching various awareness programs across the developed & developing countries to increase awareness regarding awareness for traveler’s diarrhea treatment. Increasing government initiative and awareness programs is expected to increase demand for traveler's diarrhea treatment and is working as a driver for the traveler’s diarrhea treatment market.
Increasing research and development for Traveler’s Diarrhea Treatment
Increasing prevalence of traveler’s diarrhea is leading various researchers and manufactures to increase their research and development activities for development of traveler’s diarrhea for the treatment of traveler’s diarrhea. Various manufactures from all over the world have applied for most promising traveler’s diarrhea which is currently in different regulatory approval phases. However, various manufacturers have already launched their product portfolio for traveler’s diarrhea. Increasing research and development activities for traveler’s diarrhea treatment is fulfilling increased demand of traveler’s diarrhea drugs for treatment of traveler’s diarrhea. Due to which Increasing research and development for traveler’s diarrhea drugs is working as a driver for the traveler’s diarrhea treatment market.
Top companies (Bayer AG, Merck & Co., Inc, Johnson & Johnson Services, Inc, and Novartis AG) constitute more than XX% share of the global Traveler’s Diarrhea Treatment. Other companies profiled in the report include: Valneva SE, Shanghai United Cell Biotechnology Co.,Ltd, PaxVax, Inc, Immuron, Salix Pharmaceuticals, F. Hoffmann-La Roche Ltd, Basilea Pharmaceutica Ltd, Eli Lilly and Company, Delcath Systems Inc, BridgeBio Inc, and Agios, Inc Some of the key developments are listed below:
● In 2018, Cosmo Pharmaceuticals N.V. has received U.S. Food and Drug Administration (FDA) approval for AEMCOLO (Rifamycin). AEMCOLO is developed for treatment of Travelers’ Diarrhea. The approval will help the company to expand its market portfolio.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.